NRx Pharmaceuticals (NRXP) said Wednesday that it has submitted an application for Emergency Use Authorization to the US Food and Drug Administration for the use of ZYESAMI or aviptadil in patients with Critical COVID-19 who are at immediate risk of death from Respiratory Failure despite treatment with approved therapy including remdesivir and who are ineligible for enrollment into the ongoing ACTIV-3b NIH-sponsored trial.
The company noted that patients treated with ZYESAMI vs. placebo demonstrated statistically significant, 2.8-fold increased odds of being alive and free of respiratory failure at day 28 and day 60 and a 4-fold increased odds of surviving to 60 days.
The company stated that patients at highest risk - those on ventilators at time of randomization - demonstrated a 10-fold increased odds of survival.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.